Transcriptomics Plus ‘Immune Tolerance’ of Normal Tissue Shows Promise in Lung Cancer Prognosis
Posted: Tuesday, September 27, 2022
News
Survival-predicting algorithm passes first big test in patients with lung cancer
Posted: Tuesday, September 20, 2022
InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
Posted: Monday, June 06, 2022
SPRING Phase I trial results published in Cancer Medicine, Wiley
Posted: Monday, March 28, 2022
JIPO and WIN Join Forces to Promote Immunotherapy and Precision Oncology in 2022
Posted: Monday, January 10, 2022
WIN SPRING 2021 Newsletter
Posted: Thursday, May 20, 2021
Transcriptomic Algorithm Shows Ability to Predict Progression-Free Survival
Posted: Friday, April 30, 2021
WIN’s Digital Display Precision Predictor biomarker to guide cancer targeted therapy
Posted: Friday, April 30, 2021
Behind the Paper: Digital Display Precision Predictor: the prototype of a global biomarker model
Posted: Friday, April 30, 2021
Gustave Roussy Joins the Worldwide Innovative Network (WIN) in Personalized Cancer Medicine
Posted: Thursday, April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments
Posted: Wednesday, April 28, 2021